StockUS listing USARMPAMEXHealthcareStructurally Challenged

Armata Pharmaceuticals Inc(ARMP) Stock Analysis | Healthcare

USD --+0.00%
Reward33Low
Risk83High
75%Data
Revenue growing 174% YoY
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 112.69M
Reward Ratingⓘ33 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ83 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ARMP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Armata Pharmaceuticals Inc?

operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

AI Brief Pro

The brief on Armata Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Armata Pharmaceuticals Inc?

operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 112.69M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap112.69M
Beta1.634
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.